Skip to content

R. Silva

2 papers in the library · 1 citation · publishing 2022-2025

Papers

Therapeutic use of ayahuasca: a review of the evidence of its use in approaching depressive disorders

European psychiatry June 1, 2022 G. Simões, S. Jesús, R. Silva 1 citation

Ayahuasca, a psychotropic plant used by indigenous Amazonians, shows promise for treating depression. A review of six studies found that ayahuasca use was associated with reductions in depression scale scores, significant antidepressant effects, and improved grief symptoms. It also increased introspection, positive mood, self-acceptance, empathy, openness, and emotional processing. However, the evidence comes from small, variable studies, including retrospective and prospective observational studies, a meta-analysis, and a narrative review. The authors conclude that the results are promising but require further investigation in controlled trials with larger samples to better assess clinical effects, safety, and short- and long-term outcomes.

Comparative efficacy and acceptability of psilocybin-ketamine and typical antidepressants for major depressive disorder management: a network meta-analysis

DELOS Desarrollo Local Sostenible December 11, 2025 Pedro Rodrigues, Weliton Rodrigues Dos Santos Júnior, Ivan de Sousa Araújo et al.

A systematic review and network meta-analysis of 149 randomized controlled trials compared psilocybin, ketamine, and several common antidepressants (escitalopram, bupropion, paroxetine, fluoxetine, sertraline, venlafaxine) against placebo for major depressive disorder. All antidepressants were more effective than placebo, but psilocybin and ketamine achieved the lowest depressive symptom scores and reduced suicidal ideation. For acceptability (measured by dropout rates), placebo outperformed all drugs; however, among the medications, psilocybin had the highest combined ranking for efficacy and acceptability, followed closely by ketamine. The authors suggest these two agents may aid physicians in therapeutic decision-making, including for treatment-refractory depression.